Anke Biotechnology: LV009 Expected to Enter Efficacy Evaluation Phase in Half a Month

People's Finance News, November 12thANKEBIO(300009) ANKEBIO mentioned during an institutional research meeting yesterday that its participating company, Bo sheng ji medicine science and technology (suzhou) co., LTD, has designed an accelerated dose escalation plan for In vivo CAR-T LV009. The first patient has just been enrolled, and it is expected to enter the efficacy evaluation stage in about half a month. Subsequent patients are currently being screened simultaneously. To obtain relevant data as soon as possible, Bo sheng ji has initiated ethical reviews at three hospitals to support the IND application and gather materials for business development.